Clinical trials: Gabapentin
Diabetic Peripheral Neuropathic Pain
Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management
This is a multicenter, randomized, open-label, parallel, Phase 4 clinical trial to compare efficacy and safety of gabapentin/B-complex versus pregabalin in diabetic peripheral neuropathy pain (DPNP) management.
- Trial name
- NCT01364298
- Testing
- Gabapentin/B-complex, Pregabalin
- Where
- Mexico
- Volunteers
- 353 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Intractable Pain
A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain
The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.
- Trial name
- NCT00414466
- Testing
- Intraspinal Gabapentin
- Where
- 14 sites in United States
- Volunteers
- 254 people
- Sponsor
- MedtronicNeuro
Diabetic Neuropathy
A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy
The purpose of this study is to evaluate the effectiveness and safety of tramadol hydrochloride (HCl) 37.5 miligram (mg)/acetaminophen 325 mg compared to gabapentin in participants with diabetic neuropathic (nerve disorder caused…
- Trial name
- NCT00634543
- Testing
- Tramadol hydrochloride/ Acetaminophen, Gabapentin
- Volunteers
- 162 people
- Sponsor
- Janssen Korea, Ltd., Korea
Restless Legs Syndrome
Simulated Driving Study in Restless Legs Syndrome
This study was a multi center, randomized, double blind, active and placebo controlled, parallel group study to assess simulated driving performance in XP13512 treated subjects with Restless Legs Syndrome (RLS).
- Trial name
- XP083 (NCT01332318)
- Testing
- XP13512, Diphenhydramine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00311363
- Testing
- GEn (XP13512)
- Volunteers
- 327 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00333359
- Testing
- XP13512 (GEn)
- Volunteers
- 581 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00365352
- Testing
- XP13512 600MG, XP13512 1200MG
- Volunteers
- 325 people
- Sponsor
- XenoPort, Inc.
Neuralgia, Postherpetic
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
- Trial name
- NCT00617461
- Testing
- GEn 1200mg/day, GEn 3600mg/day
- Where
- 53 sites in United States, Germany
- Volunteers
- 96 people
- Sponsor
- XenoPort, Inc.
Neuralgia, Postherpetic
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
- Trial name
- NCT00619476
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 83 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- XenoPort, Inc.
Neuropathy, Diabetic
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)
- Trial name
- NCT00643760
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 90 sites in United States
- Volunteers
- 421 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
- Trial name
- NCT00748098
- Testing
- GSK1838262 Extended Release Tablets
- Where
- 24 sites in United States
- Volunteers
- 136 people
- Sponsor
- XenoPort, Inc.
Breast Cancer, Hot Flashes
Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.
Premenopausal women with breast cancer who receive endocrine therapy (e.g. tamoxifen) and/or chemotherapy are at risk for experiencing premature menopause because of their treatment.
- Trial name
- NCT00711529
- Testing
- Hypnotherapy, gabapentin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Opioid Dependence, Opioid Withdrawal
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease…
- Conditions
- Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
- Trial name
- Detox (NCT01262092)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arkansas
Opioid-Induced Hyperalgesia
Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?
Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complicating the pain states suffered…
- Trial name
- NCT01210079
- Testing
- Gabapentin;
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Hot Flashes
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT00755417
- Testing
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg
- Where
- 45 sites in United States
- Volunteers
- 541 people
- Sponsor
- Depomed
Neuralgia,Postherpetic
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control.
- Trial name
- NCT00636636
- Testing
- Gabapentin Extended Release tablets
- Where
- 39 sites in United States, Argentina and 1 more
- Volunteers
- 452 people
- Sponsor
- Depomed
Hot Flashes
Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women
- Trial name
- NCT00777023
- Testing
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg
- Where
- 45 sites in United States
- Volunteers
- 565 people
- Sponsor
- Depomed
Post Herpetic Neuralgia, PHN
A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4% amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)
- Conditions
- Post Herpetic Neuralgia, PHN, Neuropathy, Nerve Pain
- Trial name
- NCT00475904
- Testing
- EpiCept-NP-1 Cream, Gabapentin Capsules
- Where
- India
- Volunteers
- 360 people
- Sponsor
- EpiCept Corporation
Diabetic Neuropathy, Painful
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to…
- Trial name
- NCT00385671
- Testing
- duloxetine hydrochloride, pregabalin, gabapentin
- Where
- 9 sites in United States, Germany
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Cocaine Dependence, Depressive Symptoms
Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans
To examine the clinical efficacy of sertraline (200 mg/day) alone or sertraline in combination with gabapentin. The purpose of this study is to examine whether the antidepressant sertraline alone or combined with gabapentin…
- Trial name
- NCT00654953
- Testing
- sertraline, gabapentin
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Arkansas